Entrepreneur UK's London 100: Puresport
Industry: Sport
Puresport is one of the UK's fastest-growing sports nutrition and lifestyle brands, but it wasn't built in a lab or a boardroom. It started with two rugby players searching for a better way to recover.
Co-founders Adam Ashe and Grayson Hart began exploring natural alternatives that could support the body without compromise. What began as a personal journey soon evolved into a purpose-led mission.
They were joined by fellow teammate Dan Temm, now the brand's CEO, and together they have grown Puresport from a niche startup into a community-driven movement.
With products now spanning recovery, performance, and daily wellness, Puresport is redefining what a supplement brand can be.
The start-up's rise has been fuelled by its unique ability to create emotional resonance in a crowded space. Rather than focusing solely on elite performance, Puresport speaks to the everyday runner, the parent chasing their best, and the person getting up early to put in the work.
Its tagline, For the Long Run, encapsulates its philosophy: rejecting quick fixes in favour of long-term commitment, resilience, and progress.
The company has gone from garage-packing to significant investment to delivering over £13.5m in sales.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Italy appoint Gennaro Gattuso as new manager
The Italy National Team have replaced Luciano Spalletti with Gennaro Gattuso as the new manager. An update from Fabrizio Romano confirmed the managerial agreement between Gennaro Gattuso and the Italian National Team representatives. The former World Cup champion with the Azzurri is set to be appointed at the helm of the side to lead them at the next biggest tournament in football. Advertisement Spalletti became certain of his departure during the World Cup qualifiers, and he was practically out of the team when Italy played against Moldova. A statement by Italian legend Gianluigi Buffon verified the reports as he said, 'Gattuso has become the new Italy coach, we made the best possible decision.' Gattuso was a key player of the 2006 Italy National Team, which won the World Cup in Germany under manager Marcello Lippi. He formed an impeccable partnership with Andrea Pirlo in the midfield, and it was crucial to earn the Azzurri their fourth star on their crest. Trambak Bhattacherjee | GIFN
Yahoo
20 minutes ago
- Yahoo
If EPS Growth Is Important To You, Johnson Matthey (LON:JMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Johnson Matthey (LON:JMAT). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Recognition must be given to the that Johnson Matthey has grown EPS by 54% per year, over the last three years. Growth that fast may well be fleeting, but it should be more than enough to pique the interest of the wary stock pickers. Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Johnson Matthey's EBIT margins are flat but, worryingly, its revenue is actually down. Suffice it to say that is not a great sign of growth. The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers. View our latest analysis for Johnson Matthey Fortunately, we've got access to analyst forecasts of Johnson Matthey's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting. Investors are always searching for a vote of confidence in the companies they hold and insider buying is one of the key indicators for optimism on the market. This view is based on the possibility that stock purchases signal bullishness on behalf of the buyer. Of course, we can never be sure what insiders are thinking, we can only judge their actions. Shareholders in Johnson Matthey will be more than happy to see insiders committing themselves to the company, spending UK£234k on shares in just twelve months. This, combined with the lack of sales from insiders, should be a great signal for shareholders in what's to come. We also note that it was the CEO & Director, Liam Condon, who made the biggest single acquisition, paying UK£134k for shares at about UK£13.42 each. Johnson Matthey's earnings per share have been soaring, with growth rates sky high. Growth-minded people will be intrigued by the incredible movement in EPS growth. And indeed, it could be a sign that the business is at an inflection point. If this these factors intrigue you, then an addition of Johnson Matthey to your watchlist won't go amiss. You still need to take note of risks, for example - Johnson Matthey has 4 warning signs (and 1 which is a bit concerning) we think you should know about. Keen growth investors love to see insider activity. Thankfully, Johnson Matthey isn't the only one. You can see a a curated list of British companies which have exhibited consistent growth accompanied by high insider ownership. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
